Italy’s Recordati Industria Chimica & Farmaceutica SPA reported OTC sales up by 0.3% to €178m ($195m) in the first half of 2024, as lower demand for cold and flu products held back growth.
Within that total figure, turnover from the company’s OTC corporate products – which Recordati defines as those sold directly in...






